1. Febrile Neutropenia in a Patient with Non-Small Cell Lung Cancer Treated with the Immune-Checkpoint Inhibitor Nivolumab
- Author
-
Kuniaki Shirao, Erina Watanabe, Satoshi Ohtani, Yasushi Hisamatsu, and Ryotaro Morinaga
- Subjects
Male ,medicine.medical_specialty ,Lung Neoplasms ,Prednisolone ,Adrenal Gland Neoplasms ,Adenocarcinoma of Lung ,030204 cardiovascular system & hematology ,Neutropenia ,Gastroenterology ,Methylprednisolone ,03 medical and health sciences ,0302 clinical medicine ,Antineoplastic Agents, Immunological ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,Granulocyte Colony-Stimulating Factor ,medicine ,Humans ,Lung cancer ,Pneumonitis ,Febrile Neutropenia ,Hepatitis ,business.industry ,Brain Neoplasms ,Liver Diseases ,General Medicine ,Articles ,Middle Aged ,medicine.disease ,Nivolumab ,030220 oncology & carcinogenesis ,Adenocarcinoma ,Liver function ,business ,Febrile neutropenia ,Agranulocytosis - Abstract
Patient: Male, 57-year-old Final Diagnosis: Febrile neutropenia Symptoms: Fever Medication: Nivolumab Clinical Procedure: Chemotherapy Specialty: Oncology Objective: Adverse events of drug therapy Background: Nivolumab is a human IgG4 monoclonal antibody against human programmed cell death 1 (PD-1). It has demonstrated efficacy against metastatic non-small cell lung cancer (NSCLC). Treatment with nivolumab is sometimes associated with immune-related adverse events (ir AEs) in patients. These specific ir AEs include pneumonitis, hypothyroidism, dermatitis, enterocolitis, hepatitis, and neuropathy. However, hematological toxicity is rare. Case Report: A 57-year-old man with lung adenocarcinoma, with brain and adrenal gland metastases, was therefore started on nivolumab therapy as third-line treatment. After administration of the second dose with nivolumab, grade 3 febrile neutropenia (FN) and grade 2 liver dysfunction developed in the patient. The patient was started to on intravenous antibiotics, granulocyte colony-stimulating factor (G-CSF), and corticosteroids. Neutrophil counts and liver function gradually improved, and corticosteroids were tapered over 6 weeks. However, the patient was re-treated with G-CSF because the neutrophil counts decreased again. Conclusions: Care needs to be taken with such patients because neutropenia due to treatment with nivolumab can recur, as well as other ir AEs.
- Published
- 2020